GlassScriptPhysician profile
Matthew T Stritt
NPI 1578720058
$5,645.86
in general payments reported to CMS, 2019-2025
30 companies · $504 in 2025
The $504 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $372 · 2020: $100 · 2021: $436 · 2022: $1,926 · 2023: $230 · 2024: $2,077 · 2025: $504.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,445 · Travel and Lodging: $1,367.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,444.69 |
| Travel and Lodging | $1,366.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ethicon INC. | $1,857.16 | 2022-2023 | Monarch Platform |
| Medical Device Business Services, INC. | $1,548.51 | 2024 | Monarch |
| Astrazeneca Pharmaceuticals LP | $564.23 | 2019-2025 | Fasenra, Airsupra, Tezspire |
| Glaxosmithkline, LLC. | $416.36 | 2019-2024 | Trelegy Ellipta, Nucala |
| United Therapeutics Corporation | $138.15 | 2024-2025 | |
| Amgen INC. | $119.82 | 2021-2025 | Tezspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $114.91 | 2019-2025 | Ofev, Jascayd |
| Grifols USA, LLC | $108.84 | 2021-2025 | Prolastin-C Liquid |
| Insmed, INC. | $90.24 | 2019-2025 | Brinsupri, Arikayce |
| Inspire Medical Systems, INC. | $74.24 | 2024-2025 | Inspire |
| Takeda Pharmaceuticals U.S.A., INC. | $72.48 | 2020-2024 | Glassia |
| Genzyme Corporation | $57.33 | 2020-2021 | |
| Mylan Specialty L.P. | $55.29 | 2019-2024 | Yupelri |
| Regeneron Healthcare Solutions, INC. | $53.78 | 2022-2025 | Dupixent |
| Harmony Biosciences LLC | $41.88 | 2022-2023 | Wakix |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verona Pharma, INC. | $40.47 | 2025 | Ohtuvayre |
| Jazz Pharmaceuticals INC. | $30.44 | 2021-2024 | |
| Pfizer INC. | $27.53 | 2025 | |
| Merck Sharp & Dohme LLC | $26.41 | 2024 | Keytruda |
| Philips North America LLC | $25.06 | 2019-2022 | |
| Viatris Specialty LLC | $24.33 | 2025 | Yupelri |
| Olympus America INC. | $23.69 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $21.08 | 2021 | |
| Sanofi-Aventis U.S. LLC | $18.83 | 2021 | |
| Baxter Healthcare | $18.41 | 2024 | Hillrom - Vest System Model 105 Home Care |
| Lilly USA, LLC | $16.03 | 2025 | Zepbound |
| Shire North American Group INC | $15.85 | 2019 | |
| Ceribell, INC. | $15.83 | 2025 | Pocket Eeg Device |
| Janssen Pharmaceuticals, INC | $15.17 | 2022 | |
| Pulmonx Corporation | $13.51 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Stritt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.